IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma.
Publications
Statins may reduce disease recurrence in patients with ulcerated primary melanoma
This study was undertaken to determine if long?term statin use commenced before the diagnosis of a primary melanoma is correlated with decreased risk of melanoma recurrence.
Upregulated histone deacetylase 6 associates with malignant progression of melanoma and predicts the prognosis of patients
Whether histone deacetylase 6 (HDAC6) has predictive value for the prognosis of patients suffering from cutaneous melanoma, was investigated herein.
Trends in malignant melanoma mortality in 31 countries from 1985 to 2015
Researchers used the World Health Organization Mortality Database to describe malignant melanoma (MM) mortality trends between 1985 and 2015 for 31 countries which met the inclusion criteria.